All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Thyroid cancer, which is the most common malignancy in the endocrine system, is highly curable\[[@pone.0187968.ref001]\]. However, the increased incidence of differentiated thyroid carcinoma (DTC) is a serious problem\[[@pone.0187968.ref002]\]. Recent research has focused on the pathogenesis of this malignancy, with genetic factors being suggested to play an crucial role in the carcinogenesis of DTC\[[@pone.0187968.ref003]\]. Increasing efforts are being devoted to identifying susceptibility loci for this disease and its clinical phenotype. As the most common variants in the population, single nucleotide polymorphisms (SNPs) have the potential to be diagnostic, monitoring, and prognostic biomarkers for DTC.

The *RET* (rearranged during transfection) proto-oncogene has attracted much interest in DTC because aberrant activation of *RET* by somatic rearrangements or point mutations is a unique genetic event in DTC, which also plays a significant role in thyroid carcinogenesis\[[@pone.0187968.ref004], [@pone.0187968.ref005]\]. The protein encoded by *RET* functions as a multicomponent complex in which RET binds to a ligand belonging to the glial cell line--derived neurotrophic factor family\[[@pone.0187968.ref006]\]. In our previous work, we confirmed the association of *RET* rearrangements with DTC susceptibility and clinical phenotype in the Chinese population\[[@pone.0187968.ref007], [@pone.0187968.ref008]\]. To date, however, a systematic study of association between thecommon SNP of RET and susceptibility to DTC and its clinical phenotype has not been performed.

The levels of serum thyroid stimulating hormone (TSH), free triiodothyronine (fT3) and thyroxine (fT4), thyroglobulin (TG), and anti-thyroid peroxidase antibody (ATPO) are routine testing in the patients with thyroid cancer. These factors determine the balance of thyroid hormone homeostasis. Whether the common SNP in RET oncogene affects the thyroid function in DTC patients remains unclear and requires further study.

The *RET* gene is located at 10q11.2 and comprises 20 exons and 21 introns. To date, hundreds of SNPs in this gene have been revealed. However, information connecting *RET* SNPs with susceptibility to DTC is very limited. To assess comprehensively the role of *RET* genetic polymorphism, we adopted a candidate gene association study strategy with seven selected potentially functional tagging SNPs (tagSNPs) in *RET*\[[@pone.0187968.ref009]\]. We examined their individual and combined effects on the risk of DTC and their relationship with clinical severity and thyroid function.

Material and methods {#sec006}
====================

Study subjects {#sec007}
--------------

This protocol was approved by the Ethics Committee of Sun Yat-sen University Cancer Center, Guangdong, China. Written informed consent was obtained from all patients at their first visit. For the genetic association study, a total of 552 subjects, comprising 300 DTC cases and 252 healthy control subjects, were included. The blood collection took place when the patients first visited this center. All the included subjects were recruited from Sun Yat-sen University Cancer Center in Guangzhou of Guangdong Province, China, between July 2011 and June 2016. We excluded two DTC patients from further analysis because of a past history of breast cancer or lung cancer. The healthy subjects comprised individuals with normal manifestation of the thyroid gland and thyroid function under ultrasound and serum examination. Healthy subjects who had a history of nodular goiter, Hashimoto\'s thyroiditis, or other benign thyroid diseases, and who had a history of other malignancies, were excluded.

Data collection {#sec008}
---------------

Medical records and surgical pathology reports were reviewed by Caiyun He, Yongle Jiang and Xuan Su. Information of demographic parameters, pathological characteristics of the tumors, and thyroid function parameters were collected. Slides were reviewed independently by two pathologists to confirm the diagnosis of DTC and concomitant thyroid benign diseases, such as nodular goiter and Hashimoto\'s thyroiditis. Information on the primary tumor size, stage grouping, extrathyroid extension, and metastasis were assessed based on the National Comprehensive Cancer Network (NCCN Guidelines, Version 1, 2016) on thyroid cancer recommendations (<https://www.nccn.org/>). The clinicopathological features of T, N and M stages and extrathyroid extension are well-known parameters indicating the clinical severity of thyroid cancer. The measurement and distribution of the clinicopathological features of thyroid cancer patients were showed in [S1 Table](#pone.0187968.s001){ref-type="supplementary-material"}.

TagSNP selection {#sec009}
----------------

HapMap genotype data of the Chinese Han Beijing (CHB) population (Release 27, Phase I +II +III, <http://www.HapMap.org>) were extracted within extended gene regions of *RET* in 2016, which encompassed 2 kb of upstream and downstream flanking sequence. The CHB *RET* gene has 33 common SNPs. As described in our previous studies, tagSNPs were selected by using the Haploview software\[[@pone.0187968.ref010], [@pone.0187968.ref011]\]. Briefly, tagSNPs were chosen initially based on pairwise linkage disequilibrium information to maximally represent (r2 \> 0.8) common SNPs (minor allele frequency (MAF) \> 0.05) by Haploview 4.2. We then used bioinformatics search to prioritize the tagSNPs for genotyping, based on their predicted functional effects (<http://snpinfo.niehs.nih.gov/>). For example, rs1799939 was predicted to be located at a splicing site, suggesting a potential effect on this gene\'s splicing regulation.

DNA isolation and genotyping of RET tagSNPs {#sec010}
-------------------------------------------

For each subject, 3 mL of fasting blood was collected for DNA isolation. Genomic DNA was isolated from peripheral blood lymphocytes by the routine phenol--chloroform method, as previously described\[[@pone.0187968.ref010], [@pone.0187968.ref011]\]. Each DNA sample was diluted to a working concentration of 50 ng/μL for genotyping. Assay design and SNP genotyping were performed by Gene Company Limited (Shanghai, China) using the KASPar platform according to the manufacturer's instructions\[[@pone.0187968.ref012]\]. All samples were randomized on 384-well plates and blinded for disease status. Twenty randomly selected samples were genotyped repeatedly, and the results were 100% concordant.

Statistical analysis {#sec011}
--------------------

The Hardy-Weinberg Equilibrium (HWE) of the genotype distribution of each SNP was detected by a chi-square test in the control group. The odds ratio (OR) and corresponding 95% confidence interval (CI) were calculated to measure the strength of the association between the genotype and the risk of DTC. The genetic effect of a single tagSNP on disease risk was detected by Logistic regression analysis controlling for sex and age. For the haplotype analysis of the seven RET tagSNPs (rs17028, rs1799939, rs1800858, rs1800860, rs2075912, rs2565200, and rs2742240), we set the other haplotypes pooled together as a reference, and assessed the genetic effect of each haplotype with a frequency of at least more than 0.03 in the healthy controls.

For the association analysis between the genotype and clinicopathological features, we only performed association analysis in DTC patients since the control subjects have normal manifestation of thyroid. Logistic regression analysis adjusting for sex and age was employed. For the analysis of thyroid function, the difference of fT3, fT4, TSH, Anti-TG, TG, PTH and calcitonin levels between two groups were compared by the Mann--Whitney U test because these quantitative variables did not follow a normal distribution. The corresponding variables are shown as the median (with 25--75% quartiles).

All these analyses were performed using SPSS 17.0 software (SPSS, Chicago, IL, USA), except for the haplotype analysis, which was performed using the online software SHEsis\[[@pone.0187968.ref013]\] (<http://analysis.bio-x.cn/myAnalysis.php>). All P values were two sided, and a P value \< 0.05 was considered statistically significant. The authenticity of this article has been validated by uploading the key raw data onto the Research Data Deposit public platform ([www.researchdata.org.cn](http://www.researchdata.org.cn/)), with the approval RDD number as RDDB2017000172.

Results {#sec012}
=======

Functional prediction of tagSNPs {#sec013}
--------------------------------

Seven tagSNPs in *RET* with potential functions were included in this study and their predicted functional effects are summarized in [Table 1](#pone.0187968.t001){ref-type="table"}. Among the seven tagSNPs, rs1799939, rs1800858, and rs1800860 are located within exon regions and were predicted to affect exonic splicing enhancer (ESE) or exonic splicing silencer (ESS) binding site activity, or even abolish a protein domain. The other four tagSNPs, rs17028, rs2075912, rs2565200, and rs2742240 are located in 3' untranslated region (UTR) and were predicted to be located within microRNA (miRNA) binding sites. The distribution of the genotype frequencies of the seven tagSNPs in healthy controls obeyed the Hardy-Weinberg equilibrium test ([Table 1](#pone.0187968.t001){ref-type="table"}, all P \> 0.05). Therefore, these seven tagSNPs were included for the association analysis.

10.1371/journal.pone.0187968.t001

###### Functional prediction of seven tagSNPs of the RET gene.

![](pone.0187968.t001){#pone.0187968.t001g}

  SNP         Position   Allele   TFBS   Splicing (ESE or ESS)   miRNA   nsSNP   HWE
  ----------- ---------- -------- ------ ----------------------- ------- ------- -------
  rs17028     3\' UTR    C/T      ---    ---                     Y       ---     0.123
  rs1799939   exon       A/G      ---    Y                       ---     Y       0.864
  rs1800858   exon       A/G      ---    Y                       ---     ---     0.945
  rs1800860   exon       A/G      ---    Y                       ---     ---     0.258
  rs2075912   3\'UTR     C/T      ---    ---                     Y       ---     0.391
  rs2565200   3\'UTR     T/C      ---    ---                     Y       ---     0.320
  rs2742240   3\'UTR     A/T      ---    ---                     Y       ---     0.319

Abbreviation: ESE, splicing Enhancers; ESS, exonic Splicing Silencers; HWE, Hardy--Weinberg equilibrium; nsSNP, nonsynonymous single nucleotide polymorphism; miRNA, microRNA; RET, rearranged during transfection proto-oncogene; tagSNP, tagging single nucleotide polymorphism; TFBS, transcription factor binding site; UTR, untranslated region; Y, yes.

Association between RET tagSNPs and susceptibility, clinicopathological features, and thyroid function of DTC {#sec014}
-------------------------------------------------------------------------------------------------------------

When we considered the influence of the *RET* tagSNPs on susceptibility to DTC, none of the seven tagSNPs showed an association with risk of DTC ([Table 2](#pone.0187968.t002){ref-type="table"}, all P \> 0.05). In the subgroup analysis, rs1799939 AG or AG plus AA genotypes showed an association with increased risk for the DTC cases without concomitant thyroid benign diseases (OR = 1.93 and 1.88, respectively, see [S2 Table](#pone.0187968.s002){ref-type="supplementary-material"}). No association was found between RET SNPs and the risk of DTC cases with concomitant thyroid benign diseases (see [S3 Table](#pone.0187968.s003){ref-type="supplementary-material"}).

10.1371/journal.pone.0187968.t002

###### Association between RET tagSNP and susceptibility to thyroid cancer.

![](pone.0187968.t002){#pone.0187968.t002g}

  TagSNP            Control (%)   Cancer (%)    OR (95%CI)          *P for overall*   *P*
  ----------------- ------------- ------------- ------------------- ----------------- ----------------------------------------------
  **rs17028**                                                                         0.186[^a^](#t002fn001){ref-type="table-fn"}
  CC                139 (57.0%)   174 (59.2%)   1 (ref)                               
  TC                96 (39.3%)    101 (34.4%)   0.80 (0.56--1.16)                     0.239
  TT                9 (3.7%)      19 (6.5%)     1.65 (0.72--3.79)                     0.240
  Dominant model                                0.89 (0.63--1.25)                     0.493
  Recessive model                               1.79 (0.79--4.06)                     0.161
  **rs1799939**                                                                       0.703 [^a^](#t002fn001){ref-type="table-fn"}
  GG                194 (78.2%)   220 (75.1%)   1 (ref)                               
  AG                51 (20.6%)    69 (23.5%     1.19 (0.79--1.80)                     0.407
  AA                3 (1.2%)      4 (1.4%)      1.08 (0.24--4.92)                     0.920
  Dominant model                                1.19 (0.79--1.78)                     0.403
  Recessive model                               1.10 (0.24--5.01)                     0.898
  **rs1800858**                                                                       0.880 [^a^](#t002fn001){ref-type="table-fn"}
  GG                77 (30.8%)    87 (29.8%)    1 (ref)                               
  GA                123 (49.2%)   143 (49.0%)   1.08 (0.73--1.60)                     0.715
  AA                50 (20.0%)    62 (21.2%)    1.13 (0.69--1.84)                     0.628
  Dominant model                                1.07 (0.74--1.55)                     0.709
  Recessive model                               1.10 (0.72--1.68)                     0.655
  **rs1800860**                                                                       0.463 [^a^](#t002fn001){ref-type="table-fn"}
  GG                143 (57.9%)   187 (63.2%)   1 (ref)                               
  GA                94 (38.1%)    99 (33.4%)    0.80 (0.56--1.14)                     0.220
  AA                10 (4.0%)     10 (3.4%)     0.85 (0.34--2.11)                     0.721
  Dominant model                                0.80 (0.57--1.14)                     0.218
  Recessive model                               0.93 (0.38--2.29)                     0.873
  **rs2075912**                                                                       0.371 [^a^](#t002fn001){ref-type="table-fn"}
  CC                63 (25.7%)    86 (29.1%)    1 (ref)                               
  CT                129 (52.7%)   139 (47.0%)   0.79 (0.53--1.19)                     0.259
  TT                53 (21.6%)    71 (24.0%)    1.00 (0.62--1.63)                     0.986
  Dominant model                                0.85 (0.58--1.25)                     0.410
  Recessive model                               1.18 (0.79--1.77)                     0.425
  **rs2565200**                                                                       0.313 [^a^](#t002fn001){ref-type="table-fn"}
  GG                64 (25.9%)    86 (29.3%)    1 (ref)                               
  GA                131 (53.0%)   138 (46.9%)   0.78 (0.52--1.18)                     0.238
  AA                52 (21.1%)    70 (23.8%)    1.03 (0.63--1.67)                     0.909
  Dominant model                                0.85 (0.58--1.25)                     0.414
  Recessive model                               1.22 (0.81--1.83)                     0.349
  **rs2742240**                                                                       0.361 [^a^](#t002fn001){ref-type="table-fn"}
  TT                65 (26.1%)    85 (28.9%)    1 (ref)                               
  TA                132 (53.0%)   139 (47.3%)   0.80 (0.54--1.20)                     0.284
  AA                52 (20.9%)    70 (23.8%)    1.05 (0.64--1.70)                     0.855
  Dominant model                                0.88 (0.60--1.28)                     0.496
  Recessive model                               1.22 (0.81--1.84)                     0.340

^a^, the overall p-value for 2-df comparison of the three genotype groups for each SNP. Logistic regression analysis adjusting for sex and age was implemented. Abbreviation: ref, reference; tagSNP, tagging single nucleotide polymorphism; OR, odds ratio.

We further analyzed the relationship between *RET* tagSNPs and the clinicopathological features of DTC ([Table 3](#pone.0187968.t003){ref-type="table"}). When compared with the CC or CC plus TC genotypes, TT variants at rs17028 was boarderline associated with a reduced risk of developing a higher T stage exceeding T1 (for TT *vs*. CC: OR = 0.26, 95% CI: 0.08--0.85, P = 0.026; for TT *vs*. CC and TC: OR = 0.25, 95% CI: 0.08--0.78, P = 0.017), and seemed to associated with a reduced risk for the occurrence of extrathyroid extension (for TT *vs*. CC: OR = 0.34, 95% CI: 0.11--1.00, P = 0.050; for TT *vs*. CC and TC: OR = 0.34, 95% CI: 0.12--0.97, P = 0.044). The rs1800860 GA variant had a 0.45-fold reduced risk for the occurrence of lymph node metastasis compared with the common GG genotype (P = 0.005); a similar effect was observed for GA plus AA variants (OR = 0.48, 95% CI: 0.28--0.83, P = 0.008).

10.1371/journal.pone.0187968.t003

###### Association between RET tagSNP and clinicopathological features of thyroid cancer.

![](pone.0187968.t003){#pone.0187968.t003g}

  TagSNP            T stage   *P*                  N stage   *P*      M stage                 *P*         Extrathyroid extension   *P*                                                        
  ----------------- --------- -------------------- --------- -------- ----------------------- ----------- ------------------------ -------------------- ------- --------- ------------------- -------
  **rs17028**                                                                                                                                                                                 
  CC                69/105    1 (ref)                        56/118   1 (ref)                             164/10                   1 (ref)                      89/84     1 (ref)             
  TC                37/64     0.75 (0.45--1.26)    0.278     35/66    0.88 (0.51--1.52)       0.640       94/7                     1.18 (0.43--3.25)    0.752   49/51     1.09 (0.66--1.80)   0.747
  TT                14/5      0.26 (0.08--0.85)    0.026     4/15     0.90 (0.56--6.45)       0.304       19/0                     /                    /       14/5      0.34 (0.11--1.00)   0.050
  Dominant model              1.06 (0.66--1.71)    0.817              0.97 (0.57--1.63)       0.896                                0.98 (0.36--2.69)    0.974             0.92 (0.57--1.48)   0.724
  Recessive model             0.25 (0.08--0.78)    0.017              1.95 (0.59--6.47)       0.277                                /                    /                 0.34 (0.12--0.97)   0.044
  **rs1799939**                                                                                                                                                                               
  GG                92/128    1 (ref)                        69/151   1 (ref)                             210/10                   1 (ref)                      112/106   1 (ref)             
  AG                30/39     0.98 (0.56--1.72)    0.941     26/43    0.60 (0.33--1.11)       0.102       63/6                     2.10 (0.71--6.15)    0.178   40/29     0.76 (0.44--1.34)   0.349
  AA                0/4       3.95 (0.38--40.82)   0.249     0/4      /                       /           4/0                      /                    /       0/4       /                   /
  Dominant model              1.07 (0.62--1.85)    0.818              0.68 (0.37--1.22)       0.196                                1.99 (0.68--5.83)    0.209             0.89 (0.52--1.54)   0.680
  Recessive model             4.75 (0.45--50.08)   0.194              /                       /                                    /                    /                 /                   /
  **rs1800858**                                                                                                                                                                               
  GG                38/49     1 (ref)                        27/60    1 (ref)                             84/3                     1 (ref)                      41/45     1 (ref)             
  GA                56/87     1.14 (0.65--1.97)    0.654     49/94    0.87 (0.47--1.62)       0.664       134/9                    1.78 (0.46--5.93)    0.407   75/67     0.89 (0.51--1.55)   0.687
  AA                27/35     0.70 (0.35--1.41)    0.317     16/46    1.52 (0.68--3.41)       0.308       58/4                     2.12 (0.43--10.42)   0.357   35/27     0.71 (0.35--1.42)   0.333
  Dominant model              0.98 (0.58--1.66)    0.953              1.06 (0.59--1.89)       0.852                                1.92 (0.52--7.07)    0.329             0.82 (0.49--1.39)   0.464
  Recessive model             0.61 (0.34--1.11)    0.103              1.68 (0.86--3.28)       0.133                                1.24 (0.38--4.07)    0.719             0.78 (0.44--1.40)   0.404
  **rs1800860**                                                                                                                                                                               
  GG                70/117    1 (ref)                        50/137   1 (ref)                             176/11                   1 (ref)                      94/92     1 (ref)             
  GA                49/50     0.78 (0.47--1.28)    0.322     42/57    **0.45 (0.26--0.78)**   **0.005**   93/6                     1.03 (0.37--2.89)    0.957   56/42     0.72 (0.44--1.20)   0.210
  AA                2/8       1.80 (0.44--7.45)    0.415     3/7      0.71 (0.16--3.13)       0.654       10/0                     /                    /       3/7       1.93 (0.47--7.97)   0.361
  Dominant model              0.84 (0.52--1.37)    0.490              **0.48 (0.28--0.83)**   **0.008**                            0.91 (0.33--2.56)    0.863             0.80 (0.49--1.30)   0.370
  Recessive model             2.19 (0.54--8.81)    0.272              1.26 (0.31--5.23)       0.748                                /                    /                 2.25 (0.56--9.09)   0.254
  **rs2075912**                                                                                                                                                                               
  CC                36/50     1 (ref)                        31/55    1 (ref)                             83/3                     1 (ref)                      43/43     1 (ref)             
  CT                56/83     0.12 (0.64--1.95)    0.691     41/98    1.23 (0.67--2.26)       0.509       130/9                    1.95 (0.50--7.560    0.335   72/65     1.00 (0.58--1.74)   0.999
  TT                29/42     0.92 (0.48--1.77)    0.795     23/48    1.28 (0.62--2.63)       0.505       66/5                     2.13 (0.48--9.45)    0.321   38/33     0.92 (0.48--1.77)   0.806
  Dominant model              1.04 (0.62--1.75)    0.872              1.27 (0.72--2.23)       0.407                                2.03 (0.56--7.33)    0.281             0.97 (0.58--1.62)   0.892
  Recessive model             0.83 (0.47--1.44)    0.500              1.12 (0.61--2.07)       0.711                                1.44 (0.48--4.34)    0.515             0.95 (0.55--1.65)   0.859
  **rs2565200**                                                                                                                                                                               
  GG                35/51     1 (ref)                        30/56    1 (ref)                             83/3                     1 (ref)                      42/44     1 (ref)             
  GA                56/82     1.04 (0.60--1.82)    0.877     39/99    1.24 (0.67--2.29)       0.491       130/8                    1.71 (0.43--6.74)    0.444   72/64     0.93 (0.54--1.62)   0.806
  AA                28/42     0.89 (0.46--1.72)    0.724     23/47    1.19 (0.58--2.45)       0.644       65/5                     2.20 (0.49--9.82)    0.301   37/33     0.90 (0.47--1.73)   0.750
  Dominant model              0.99 (0.59--1.66)    0.965              1.25 (0.71--2.20)       0.441                                1.89 (0.52--6.86)    0.336             0.92 (0.55--1.54)   0.740
  Recessive model             0.84 (0.48--1.47)    0.537              1.05 (0.57--1.94)       0.883                                1.62 (0.53--4.97)    0.396             0.97 (0.56--1.69)   0.913
  **rs2742240**                                                                                                                                                                               
  TT                35/50     1 (ref)                        31/54    1 (ref)                             82/3                     1 (ref)                      42/43     1 (ref)             
  TA                57/82     1.07 (0.62--1.87)    0.809     40/99    1.27 (0.69--2.35)       0.438       131/8                    1.67 (0.42--6.61)    0.466   73/64     0.95 (0.54--1.66)   0.855
  AA                28/42     0.90 (0.46--1.73)    0.744     23/47    1.25 (0.61--2.56)       0.551       65/5                     2.20 (0.49--9.77)    0.301   37/33     0.91 (0.47--1.75)   0.769
  Dominant model              1.02 (0.61--1.71)    0.945              2.30 (0.74--2.28)       0.365                                1.85 (0.51--6.75)    0.350             0.94 (0.56--1.58)   0.938
  Recessive model             0.86 (0.49--1.50)    0.586              1.09 (0.59--2.01)       0.783                                1.63 (0.53--4.98)    0.393             0.99 (0.57--1.72)   0.972

Logistic regression analysis adjusting for sex and age was implemented. Associations that reached statistical significance were highlighted in bold.

We also explored whether *RET* variants affect pre-operative thyroid function in DTC patients ([Table 4](#pone.0187968.t004){ref-type="table"}). Variants in the rs2075912, rs2565200 and rs2742240 loci were associated statistically with increased thyroid stimulating hormone (TSH) levels but decreased parathyroid hormone (PTH) levels. The PTH levels in DTC cases carrying GA genotype at rs1800858 site were also statistically lower than those in the wild-type carriers. In addition, subjects carrying the rare rs17028 TT homozygote genotype showed a borderline association with a higher PTH levels compared with the common CC homozygotes.

10.1371/journal.pone.0187968.t004

###### Association between RET tagSNP and pre-operative thyroid function.

![](pone.0187968.t004){#pone.0187968.t004g}

  TagSNP                                              freq           fT3               fT4            TSH              ATPO             Anti-TG          TG                PTH               Calcitonin                                                                    
  --------------------------------------------------- -------------- ----------------- -------------- ---------------- ---------------- ---------------- ----------------- ----------------- ------------ -------- ------- ------- ------- ----------- ----------- ------- -------
  Median (25%,75%) value for the total DTC patients   1.7(4.3,5.1)   16.8(15.1,18.9)   2.0(1.3,2.9)   11.1(7.1,21.3)   21.2(7.4,50.2)   21.2(7.4,50.2)   36.6(27.8,46.0)   24.4(22.0,27.6)                                                                                 
  **rs17028**                                                                                                                                                                                                                                                              
  CC                                                  168            4.66                             16.67                             2.15                               11.30                          21.01            20.50           35.66                   24.75   
  TC                                                  97             4.61              0.884          17.52            0.359            1.99             0.205             10.82             0.669        19.36    0.729   19.83   0.959   34.88       0.796       23.83   0.124
  TT                                                  19             4.66              0.689          16.79            0.364            1.71             0.105             8.90              0.338        19.69    0.916   26.17   0.151   39.52       0.048       23.77   0.528
  Dominant model                                                     0.795                            0.608                             0.098                              0.489                          0.734            0.670           0.673                   0.118   
  Recessive model                                                    0.703                            0.221                             0.177                              0.351                          0.988            0.142           0.043                   0.765   
  **rs1799939**                                                                                                                                                                                                                                                            
  GG                                                  212            4.65                             16.66                             2.04                               10.62                          21.40            21.72           35.56                   24.39   
  AG                                                  68             4.70              0.876          16.94            0.693            1.98             0.521             12.96             0.578        18.35    0.222   20.14   0.891   37.18       0.078       24.90   0.653
  AA                                                  4              4.54              0.602          17.75            0.809            2.59             0.269             10.38             0.916        160.42   0.117   55.71   0.436   36.46       0.556       23.06   0.891
  Dominant model                                                     0.965                            0.666                             0.696                              0.607                          0.392            0.978           0.069                   0.685   
  Recessive model                                                    0.571                            0.828                             0.224                              0.842                          0.086            0.427           0.619                   0.912   
  **rs1800858**                                                                                                                                                                                                                                                            
  GG                                                  85             4.66                             16.78                             1.92                               12.39                          18.73            25.51           39.19                   24.04   
  GA                                                  140            4.66              0.913          16.94            0.200            2.15             0.230             10.98             0.699        20.10    0.657   18.97   0.101   33.72       **0.003**   24.33   0.806
  AA                                                  58             4.66              0.583          16.49            0.548            2.27             0.129             10.84             0.845        20.13    0.997   25.09   0.681   37.28       0.192       25.17   0.562
  Dominant model                                                     0.897                            0.233                             0.137                              0.830                          0.737            0.166           **0.006**               0.684   
  Recessive model                                                    0.545                            0.982                             0.358                              0.730                          0.819            0.646           0.864                   0.614   
  **rs1800860**                                                                                                                                                                                                                                                            
  GG                                                  180            4.65                             16.52                             2.12                               10.66                          21.01            23.82           35.66                   24.52   
  GA                                                  96             4.69              0.968          17.28            0.121            2.00             0.581             11.59             0.738        19.78    0.859   18.24   0.323   35.94       0.614       24.12   0.893
  AA                                                  10             4.73              0.708          15.48            0.318            2.18             0.601             12.71             0.904        17.08    0.309   24.94   0.938   40.96       0.224       26.10   0.948
  Dominant model                                                     0.895                            0.230                             0.518                              0.778                          0.930            0.366           0.437                   0.913   
  Recessive model                                                    0.739                            0.238                             0.716                              0.811                          0.288            0.827           0.232                   0.892   
  **rs2075912**                                                                        0.572                           0.554                             **0.014**                           0.763                 0.933           0.747               **0.017**           0.559
  CC                                                  84             4.67                             16.82                             1.83                               11.32                          19.06            22.56           38.54                   23.83   
  CT                                                  136            4.64              0.772          16.76            0.277            2.12             **0.013**         11.20             0.474        19.60    0.874   19.96   0.434   34.50       **0.005**   24.61   0.377
  TT                                                  66             4.70              0.428          16.76            0.491            2.30             **0.008**         10.75             0.636        21.43    0.792   23.91   0.649   37.32       0.163       24.96   0.315
  Dominant model                                                     0.904                            0.285                             **0.004**                          0.476                          0.996            0.452           **0.009**               0.293   
  Recessive model                                                    0.306                            0.843                             0.162                              0.938                          0.729            0.884           0.885                   0.552   
  **rs2565200**                                                                                                                                                                                                                                                            
  GG                                                  85             4.66                             16.81                             1.83                               11.29                          19.19            23.40           38.57                   23.77   
  GA                                                  135            4.65              0.997          16.78            0.210            2.12             **0.015**         11.26             0.367        19.52    0.778   19.83   0.630   34.68       **0.004**   24.58   0.379
  AA                                                  65             4.70              0.359          16.65            0.436            2.31             **0.010**         10.74             0.589        21.50    0.826   23.25   0.618   23.58       0.116       24.94   0.357
  Dominant model                                                     0.706                            0.219                             **0.005**                          0.381                          0.911            0.385           **0.007**               0.309   
  Recessive model                                                    0.311                            0.838                             0.172                              0.956                          0.715            0.902           0.932                   0.630   
  **rs2742240**                                                                                                                                                                                                                                                            
  TT                                                  83             4.68                             16.81                             1.84                               11.29                          19.19            23.40           38.57                   23.77   
  TA                                                  136            4.64              0.853          16.76            0.263            2.12             **0.017**         11.20             0.368        19.60    0.914   19.76   0.306   34.50       **0.006**   24.51   0.443
  AA                                                  65             4.70              0.402          16.65            0.478            2.31             **0.012**         10.74             0.572        21.50    0.766   23.25   0.582   37.30       0.129       24.94   0.387
  Dominant model                                                     0.833                            0.271                             **0.006**                          0.377                          0.965            0.333           **0.010**               0.363   
  Recessive model                                                    0.295                            0.841                             0.190                              0.940                          0.721            0.903           0.956                   0.614   

^a^, Analysis performed using the Mann-Whitney test. Associations that reached statistical significance were highlighted in bold. Abbreviation: ATPO, anti-thyroid peroxidase antibody; freq, frequency; fT3, free triiodothyronine; fT4, free thyroxine; tagSNP, tagging single nucleotide polymorphism; TG, thyroglobulin; TSH, thyroid stimulating hormone; PTH, Parathyroid hormone.

Association between haplotype of RET and clinicopathological features and risk of DTC {#sec015}
-------------------------------------------------------------------------------------

For DTC susceptibility, a rare haplotype of CGGATAA of rs17028-rs1799939-rs1800858-rs1800860-rs2075912-rs2565200-rs2742240 showed a significant association with reduced risk of developing DTC, demonstrating an OR of 0.18 (95% CI: 0.06--0.54, P values for Pearson's Chi-square test or Fisher's exact test = 0.001, [Table 5](#pone.0187968.t005){ref-type="table"}).

10.1371/journal.pone.0187968.t005

###### Association between haplotypes of RET tagSNPs and susceptibility to thyroid cancer.

![](pone.0187968.t005){#pone.0187968.t005g}

  Haplotype           Case (%)       Control (%)     OR (95% CI)             Fisher\'s *P*   Pearson\'s *P*
  ------------------- -------------- --------------- ----------------------- --------------- ----------------
  C G A G T A A       234 (41.8%)    183 (40.4%)     1.12 (0.86--1.45)       0.405           0.405
  T G G G C G T       110 (19.6%)    90 (19.8%)      1.02 (0.74--1.40)       0.905           0.905
  C A G A C G T       55 (9.8%)      48 (10.6%)      0.95 (0.63--1.44)       0.810           0.810
  C G G A C G T       33 (5.8%)      28 (6.2%)       0.95 (0.57--1.61)       0.859           0.859
  C G G G C G T       48 (8.6%)      43 (9.5%)       0.92 (0.60--1.42)       0.706           0.706
  **C G G A T A A**   **4 (0.7%)**   **18 (3.9%)**   **0.18 (0.06--0.54)**   **0.001**       **0.001**
  C G G G T A A       22 (3.9%)      11 (2.3%)       1.81 (0.85--3.84)       0.118           0.118

Associations that reached statistical significance were highlighted in bold.

For the clinicopathological features of DTC, another rare haplotype CAAGCGT of rs17028-rs1799939-rs1800858-rs1800860-rs2075912-rs2565200-rs2742240 conferred increased risk for the occurrence of distant metastasis (OR = 7.57, 95% CI = 1.01--56.56, P values for Pearson's Chi-square test or Fisher's exact test = 0.009, [Table 6](#pone.0187968.t006){ref-type="table"}). No associations were observed between haplotypes of the seven *RET* tagSNPs and T stage, N stage, extrathyroid extension, number of cancer lesions, and occurrence of concomitant thyroid benign diseases in DTC (all P \> 0.05, data not shown).

10.1371/journal.pone.0187968.t006

###### Association between haplotypes of RET tagSNPs and the occurrence of distant metastasis in thyroid cancer.

![](pone.0187968.t006){#pone.0187968.t006g}

  Haplotype           Case (%)       Control (%)    OR (95% CI)              Fisher\'s P   Pearson\'s P
  ------------------- -------------- -------------- ------------------------ ------------- --------------
  **C A A G C G T**   **1 (3.6%)**   **3 (0.5%)**   **7.57 (1.01--56.56)**   **0.009**     **0.009**
  C A G A C G T       5 (17.9%)      50 (9.4%)      1.92 (0.70--5.26)        0.200         0.200
  C G A G T A A       14 (50.0%)     220 (41.6%)    1.23 (0.57--2.63)        0.597         0.597
  C G G G C G T       1 (3.6%)       47 (8.9%)      0.35 (0.05--2.62)        0.284         0.284
  C G G G T A A       1 (3.6%)       20 (3.8%)      0.88 (0.16--4.82)        0.788         0.788
  T G G G C G T       6 (21.4%)      102 (19.4%)    1.03 (0.41--2.61)        0.947         0.947

Associations that reached statistical significance were highlighted in bold.

Discussion {#sec016}
==========

Genetic variants of the proto-oncogene *RET* have attracted much research attention in recent studies of cancer causation\[[@pone.0187968.ref004], [@pone.0187968.ref005]\]. Our evaluation of a subgroup of DTC patients without concomitant thyroid benign diseases showed that DTC was more likely to occur in subjects with the rs1799939 AG or AG plus AA genotypes compared with the common GG genotype. Concerning the aggressive features of DTC, higher level of N stage was more likely to exist in subjects carrying the common homozygotes of rs1800860. Of note, higher TSH levels and lower PTH levels were found in patients with rs2075912, rs2565200, and rs2742240 heterozygotes and rare homozygotes, and similar results were observed between PTH levels and rs1800858.

We observed that the carriers with rs1799939 variants were more susceptible to DTC without concomitant thyroid benign diseases. rs1799939 is one of the most frequently studied SNPs in *RET*, and leads to an amino acid change from glycine to serine. In this study, online informatics software also predicted that rs1799939 would affect the splicing of *RET* transcripts. In another Chinese study, Huang and Yang reported that the rs1799939 AA genotype conferred a 3.76-fold increased risk of thyroid cancer\[[@pone.0187968.ref014]\]. A positive association was also reported in Khan et al.'s study in an Indian population\[[@pone.0187968.ref015]\]. However, a negative association for this SNP was found in Santos et al.'s study in a Portuguese Population\[[@pone.0187968.ref016]\]. Besides an independent effect of a single SNP, we observed an association between a rare haplotype, CGGATAA, (incorporated by rs17028-rs1799939-rs1800858-rs1800860-rs2075912-rs2565200-rs2742240 SNPs) and reduced risk of DTC, compared with other haplotypes, including the A risky allele at the rs1799939 site, which excluded chance as an explanation for the observed associations. The mechanisms by which the *RET* polymorphisms may confer an increased susceptibility to DTC remain to be determined. A pathogenic role of this SNP in DTC should be further evaluated *in vitro*.

We also found relationships between two RET tagSNPs and the aggressive features of DTC. The homozygous genotype of rs17028 showed hints of association with a reduced risk of the occurrence of a higher T stage, as well as extrathyroid extension, and the heterozygous genotype of rs1800860 contributed to a reduced risk for the occurrence of lymph node metastasis. rs17028 and rs1800860 have been reported in patients with Hirschsprung disease\[[@pone.0187968.ref017]\]. In addition, rs1800860 was reported to be associated with the risk of differentiated thyroid cancer\[[@pone.0187968.ref018]\]. This is an initial study reporting the frequencies of rs17028 and rs1800860 and their relationship with the clinicopathological features in DTC. As for the molecular function, a study focusing on kidney size in newborns suggested that rs1800860 was identified within an exonic splicing enhancer\[[@pone.0187968.ref019]\]. As predicted in this study, the variant A in the mRNA reduced the affinity for spliceosome proteins, enhanced the likelihood of aberrant mRNA splicing, and diminished the level of the functional transcript in human cells. So far, there is no known function for rs17028. The variant T allele of rs17028, located in the *RET* 3' UTR, was predicted to impair the binding affinity of miR-24. He et al.'s study suggested overexpression of miR-24 in DTC\[[@pone.0187968.ref020]\]. Therefore, we hypothesized that the weakened binding affinity of miR-24 might constrain tumor progression in DTC patients harboring the T allele. Whether this SNP affects *RET* function in DTC in this manner requires further study.

In contrast to the susceptibility and clinicopathological features, *RET* variants have rarely been evaluated in thyroid function. Among the clinical parameters of thyroid function, the most frequently affected factors are TSH and PTH, which are critical factors for monitoring patients after surgery. Our previous study found that *RET* fusion genes correlated with higher TSH levels after surgery. In this study, we found several SNPs that were related to pre-operative thyroid function, including rs2075912, rs2565200, rs2742240, and rs1800858. Strikingly, these four SNPs did not show an association with susceptibility and clinical phenotype of DTC, whilst the DTC risk and clinical phenotype associated rs1799939 and rs1800860 were not related with thyroid function. This phenomenon provoked speculation that *RET* variants exclusively affect the development of DTC and thyroid function. Among the four SNPs, rs2075912, rs2565200, and rs2742240, are located in the *RET* 3' UTR and were predicted to affect the binding of certain miRNAs. This suggested a biological function of the *RET* variants in the regulation of miRNAs that affect the synthesis of thyroid factors. Although the SNPs were not related to the susceptibility and TNM staging in DTC, it remains unclear whether these *RET* SNPs could predispose patients the recurrence of DTC, which requires further study.

It is a pity that there are several limitations in our study. In this study, the statistical analyses were performed on seven RET SNPs. And our study population is relatively small, especially for the haplotype analysis for distant metastasis in thyroid cancer; thereby, impact of RET SNPs on disease risk and disease severity might be probably underestimated. View in this manner, we considered a more conservative significance level of 0.05 rather than 0.05/7, as recommended previously\[[@pone.0187968.ref021], [@pone.0187968.ref022]\]. However, we are aware that the statistical results of our analyses should be considered to be exploratory, and hence did not adjust for multiple testing.

In conclusion, DTC without concomitant thyroid benign diseases was more likely to occur in subjects with the rs1799939 AG variant compared with those carrying the common GG genotype. An association was found between the rare haplotype CGGATAA and reduced risk of DTC compared with other haplotypes incorporating the risky A allele at rs1799939 site, which excluded chance as an explanation for the observed associations. A higher level of N stage was more likely to exist in subjects carrying the wild-type genotype at rs1800860. Notably, higher TSH levels and lower PTH levels were found in patients with rs2075912, rs2565200, and rs2742240 heterozygotes and rare homozygotes, and similar results were observed between PTH levels and the GA genotype of rs1800858.
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